Folate-targeted nanoparticle delivery of chemo-and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis ME Werner, S Karve, R Sukumar, ND Cummings, JA Copp, RC Chen, ... Biomaterials 32 (33), 8548-8554, 2011 | 205 | 2011 |
Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery S Karve, ME Werner, R Sukumar, ND Cummings, JA Copp, EC Wang, ... Proceedings of the national academy of sciences 109 (21), 8230-8235, 2012 | 183 | 2012 |
Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system F DeRosa, B Guild, S Karve, L Smith, K Love, JR Dorkin, KJ Kauffman, ... Gene therapy 23 (10), 699-707, 2016 | 174 | 2016 |
Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy ME Werner, JA Copp, S Karve, ND Cummings, R Sukumar, C Li, ... ACS nano 5 (11), 8990-8998, 2011 | 127 | 2011 |
Effect of drug release kinetics on nanoparticle therapeutic efficacy and toxicity M Sethi, R Sukumar, S Karve, ME Werner, EC Wang, DT Moore, ... Nanoscale 6 (4), 2321-2327, 2014 | 93 | 2014 |
Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza S Chivukula, T Plitnik, T Tibbitts, S Karve, A Dias, D Zhang, R Goldman, ... npj Vaccines 6 (1), 153, 2021 | 85 | 2021 |
Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models KV Kalnin, T Plitnik, M Kishko, J Zhang, D Zhang, A Beauvais, ... npj Vaccines 6 (1), 61, 2021 | 79 | 2021 |
Cns delivery of mrna and uses thereof F DeRosa, M Heartlein, S Karve US Patent App. 14/521,168, 2015 | 64 | 2015 |
The pH-dependent association with cancer cells of tunable functionalized lipid vesicles with encapsulated doxorubicin for high cell-kill selectivity S Karve, A Bandekar, MR Ali, S Sofou Biomaterials 31 (15), 4409-4416, 2010 | 58 | 2010 |
Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin A Bandekar, S Karve, MY Chang, Q Mu, J Rotolo, S Sofou Biomaterials 33 (17), 4345-4352, 2012 | 56 | 2012 |
Methods for purification of messenger RNA F DeRosa, A Dias, S Karve, M Heartlein US Patent 9,850,269, 2017 | 49 | 2017 |
Heterogeneous Domains and Membrane Permeability in Phosphatidylcholine− Phosphatidic Acid Rigid Vesicles As a Function of pH and Lipid Chain Mismatch S Karve, G Bajagur Kempegowda, S Sofou Langmuir 24 (11), 5679-5688, 2008 | 48 | 2008 |
Methods for purification of messenger RNA M Heartlein, F DeRosa, A Dias, S Karve US Patent 9,957,499, 2018 | 46 | 2018 |
The use of pH-triggered leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and therapeutic potential of targeted liposomal immunochemotherapy S Karve, A Alaouie, Y Zhou, J Rotolo, S Sofou Biomaterials 30 (30), 6055-6064, 2009 | 46 | 2009 |
pH-dependent formation of lipid heterogeneities controls surface topography and binding reactivity in functionalized bilayers GB Kempegowda, S Karve, A Bandekar, A Adhikari, T Khaimchayev, ... Langmuir 25 (14), 8144-8151, 2009 | 28 | 2009 |
mRNA therapeutics: beyond vaccine applications B Bhat, S Karve, DG Anderson Trends in Molecular Medicine 27 (9), 923-924, 2021 | 25 | 2021 |
Methods for purification of messenger RNA F DeRosa, A Dias, S Karve, M Heartlein US Patent 11,059,841, 2021 | 23 | 2021 |
Stereochemically enriched compositions for delivery of nucleic acids F Derosa, S Karve, M Heartlein US Patent 10,138,213, 2018 | 23 | 2018 |
Encapsulation of messenger RNA F DeRosa, S Karve, M Heartlein US Patent 9,668,980, 2017 | 22 | 2017 |
Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and non-human primates KV Kalnin, T Plitnik, M Kishko, J Zhang, D Zhang, A Beauvais, ... BioRxiv, 2020.10. 14.337535, 2020 | 21 | 2020 |